Distributor inventory | Tablet
Empagliflozin 10 mg + Linagliptin 2.5 mg tablet
Type 2 diabetes mellitus: adjunct to diet and exercise to improve glycaemic control; may be used when dual therapy is needed (SGLT2 inhibitor + DPP-4 inhibitor).
Empagliflozin (SGLT2 inhibitor) lowers blood glucose by increasing urinary glucose excretion from the kidneys. Linagliptin (DPP-4 inhibitor) increases incretin levels, enhancing insulin release and reducing glucagon secretion in a glucose-dependent manner.
Oral tablet. Take exactly as prescribed, usually once daily, with or without food (preferably at the same time each day). Swallow whole with water; maintain adequate hydration and follow diet/exercise advice.
Common side effects of CELAVI M 10/25MG TAB may include:
For type 2 diabetes only; not for type 1 diabetes or diabetic ketoacidosis. Risk of dehydration/low blood pressure—drink fluids and use caution in elderly/diuretics. SGLT2 inhibitors may rarely cause ketoacidosis (seek care for nausea, vomiting, abdominal pain, breathlessness), urosepsis/pyelonephritis, and genital infections (including rare Fournier’s gangrene). Monitor kidney function; empagliflozin effectiveness reduces with severe renal impairment and may be contraindicated in advanced CKD—follow prescriber advice. Stop temporarily during major surgery/acute serious illness or prolonged fasting as advised. Risk of pancreatitis is rare with DPP-4 inhibitors; stop if severe abdominal pain occurs.
